Who we are
Who we are
Board of Directors
Collaborations / Partnerships
Wockhardt HIV/AIDS Care
We touch lives
R & D
New Drug Discovery
Marketing & Regulatory Infrastructure
Frequently Asked Questions
Life at Wockhardt
Focus on Development
Meet our People
Financials at a glance
Chairman's AGM Speeches
Code of Conduct
Code of Practices & Procedures for fair disclosure of UPSI
Financial Press Releases
Chairman's letter to Shareowners
Details of Unclaimed Dividend
Filings with Stock Exchange
Committees of Board
Accounts of Subsidiaries
Who we are
Sales Revenues: US$ 1.03 billion, INR 56.10 billion (FY 2012-13)
Operating Profit (EBIDTA): US$ 384 million, INR 20.91 billion (FY 2012-13)
US Sales: US$ 531 million (FY 2012-13)
UK Sales: GBP 108 million (FY 2012-13)
Products launched globally:75 (April - September 2013)
Patents filed: 1,733 (till September 2013)
Patents granted: 228 (till September 2013)
International Offices: USA, UK, Ireland, France
Wockhardt has 3 research centres globally with over 607 scientists of which over 80 are doctorates. Its multi-disciplinary research activities encompass pharmaceutical formulations, biopharmaceutical bulk and formulations, novel drug delivery system, new drug discovery programme and process engineering for Active Pharmaceutical Ingredients.
Wockhardt's 12 manufacturing plants are located in India, UK, Ireland, US, and are compliant to international regulatory standards including US FDA and UK MHRA. These manufacturing plants are multi-technology and can manufacture all the dosage forms including sterile products as well as products with lyophilised dosage forms.
Wockhardt is the 4th company in the world to have developed recombinant insulin, Wosulin - from concept to market stage. It also developed a patented delivery device ‘Pen’ for Wosulin injections.
First Company in the world, after the originator, to have developed and marketed a long acting insulin analogue, glargine (Glaritus).
Wockhardt was four times in a row, awarded the prestigious Patent Award by the Government of India, for the ‘Maximum number of Patent Filings and Grants from India’.
Wockhardt has also received the prestigious Worldstar award in the field of packaging, this being the highest recognition in the world of packaging.
Wockhardt UK is the largest Indian Generics Company in the United Kingdom.
Wockhardt's Pinewood is the No.1 branded generics company in Ireland.
Wockhardt was ranked 76th amongst the World’s Top 100 Pharmaceutical Companies and only the 4th Indian Pharmaceutical Company in this elite 100 group (Scrip 100, 2011 edition).
Wockhardt has been a 'Business Superbrand' for two consecutive years - the only pharmaceutical & healthcare company in India to get this rare distinction.
Wockhardt’s CSR (Corporate Social Responsibility) arm under Wockhardt Foundation has touched in a short period of time, 3 million lives through its various medical and social programmes and initiatives.
Wockhardt Hospitals is associated with Partners Harvard Medical International, an international arm of Harvard Medical School, USA.
Wockhardt is amongst Top-5 in the field of Healthcare in India.
Get in touch
Terms & conditions
© 2015 wockhardt. All Rights Reserved.